BBIO Stock Up 15% after 7-Day Win Streak
BridgeBio Pharma (BBIO) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 15% return. The company has gained about $1.4 Bil in value over the last 7 days, with its current market capitalization at about $9.8 Bil. The stock remains 87.0% above its value at the end of 2024. This compares with year-to-date returns of 9.7% for the S&P 500.
BBIO provides discovery, development, and delivery of medicines for genetic diseases with a pipeline of 30 programs, including early to late-stage candidates like AG10 and BBP-265 for transthyretin stabilization. After this rally, is BBIO still a buy – or is it time to lock in gains? Deep dive with Buy or Sell BBIO.
Comparing BBIO Stock Returns With The S&P 500
The following table summarizes the return for BBIO stock vs. the S&P 500 index over different periods, including the current streak:
- How Will Constellation Brands Stock React To Its Upcoming Earnings?
- NVIDIA Stock Near Crucial Support – Buy Signal?
- Why FSLR Could Outperform NXP Semiconductors Stock
- Bloom Energy Stock Is On Sale, But Is It Still Too Expensive?
- Broadcom Stock’s AI Calm Hides Its Crash History
- The Real Downturn Risk In ON Semiconductor Stock
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | 0.3% | -0.3% |
| 7D (Current Streak) | 14.5% | 1.7% |
| 1M (21D) | 9.8% | 2.4% |
| 3M (63D) | 52.1% | 9.0% |
| YTD 2025 | 87.0% | 9.7% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
| 2022 | -54.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has BBIO behaved after prior drops? See BBIO Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 27 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 24 |
| 4D | 16 | 2 |
| 5D | 4 | 0 |
| 6D | 1 | 1 |
| 7D or more | 5 | 0 |
| Total >=3 D | 35 | 27 |
Key Financials for BridgeBio Pharma (BBIO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $9.3 Mil | $221.9 Mil |
| Operating Income | $-599.4 Mil | $-577.4 Mil |
| Net Income | $-643.2 Mil | $-535.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $116.6 Mil | $110.6 Mil |
| Operating Income | $-103.8 Mil | $-133.5 Mil |
| Net Income | $-167.4 Mil | $-181.9 Mil |
While BBIO stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.